D.Y.C. Heng

A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel

K.N. Chi, Thian Kheoh, Charles J. Ryan et al. · Annals of Oncology · 2015 · 171 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials

D.Y.C. Heng, Toni K. Choueiri, Brian I. Rini et al. · Annals of Oncology · 2013 · 147 citations · Full text

Medicine, Nephrology, Oncology +13

Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy

D.Y.C. Heng, Mary J. MacKenzie, Ulka N. Vaishampayan et al. · Annals of Oncology · 2011 · 131 citations · Full text

Medicine, Cancer Biology, Oncology +17

First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC

Jenny J. Ko, Toni K. Choueiri, Brian I. Rini et al. · British Journal of Cancer · 2014 · 70 citations · Full text

Medicine, Biostatistics, Oncology +13

Deep Vein Thrombosis is Not Rare in Asia—The Singapore General Hospital Experience

L H Lee, Kai-Peng Gu, D.Y.C. Heng · Annals of the Academy of Medicine Singapore · 2002 · 48 citations

Medicine, Hematology, Internal Medicine +17